Anemia in chronic kidney disease patients

Kausz, 2005, General medical care among patients with chronic kidney disease: opportunities for improving outcomes, J Am Soc Nephrol, 16, 3092, 10.1681/ASN.2004110910 Kausz, 2005, Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease?, Am J Kidney Dis, 45, 136, 10.1053/j.ajkd.2004.08.042 El-Achkar, 2005, Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: the Kidney Early Evaluation Program, Kidney Int, 67, 1483, 10.1111/j.1523-1755.2005.00226.x Hsu, 2002, Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey, J Am Soc Nephrol, 13, 504, 10.1681/ASN.V132504 McClellan, 2004, The prevalence of anemia in patients with chronic kidney disease, Curr Med Res Opin, 20, 1501, 10.1185/030079904X2763 Collins, 2003, Anemia management prior to dialysis: cardiovascular and cost-benefit observations, Nephrol Dial Transplant, 18, ii2 Besarab, 2000, Defining a renal anemia management period, Am J Kidney Dis, 36, S13, 10.1053/ajkd.2000.19927 Jungers, 2001, Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients, Nephrol Dial Transplant, 16, 307, 10.1093/ndt/16.2.307 Fink, 2001, Use of erythropoietin before the initiation of dialysis and its impact on mortality, Am J Kidney Dis, 37, 348, 10.1053/ajkd.2001.21305 Gouva, 2004, Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial, Kidney Int, 66, 753, 10.1111/j.1523-1755.2004.00797.x Lu, 2005, Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time, Nephron Clin Pract, 101, c79, 10.1159/000086226 Henry, 2004, Epoetin alfa: clinical evolution of a pleiotropic cytokine, Arch Intern Med, 164, 262, 10.1001/archinte.164.3.262 Sengolge, 2005, Intravenous iron therapy: well-tolerated, yet not harmless, Eur J Clin Invest, 35, 46, 10.1111/j.1365-2362.2005.01530.x Iaina, 2005, Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal syndrome, Nat Clin Pract Cardiovasc Med, 2, 95, 10.1038/ncpcardio0094 Levin, 1999, Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin, Am J Kidney Dis, 34, 125, 10.1016/S0272-6386(99)70118-6 Kliger, 2003, Anemia in chronic kidney disease: clinical implications of early management, Dial Transplant, 32, 179 Morceau, 2009, Pro-Inflammatory Cytokine-Mediated Anemia: Regarding Molecular Mechanisms of Erythropoiesis, vol. 2009 Park, 2001, Hepcidin, a urinary antimicrobial peptide synthesized in the liver, J Biol Chem, 276, 7806, 10.1074/jbc.M008922200 Ganz, 2003, Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation, Blood, 102, 783, 10.1182/blood-2003-03-0672 Donovan, 2000, Positional cloning of zebra-fish ferroportin1 identifies a conserved vertebrate iron exporter, Nature, 403, 776, 10.1038/35001596 Nemeth, 2004, Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization, Science, 306, 2090, 10.1126/science.1104742 Bosman, 2001, Anaemia with erythropoietin deficiency occurs early in diabetic nephropathy, Diabetes Care, 24, 495, 10.2337/diacare.24.3.495 Xue, 2002, Anaemia treatment in the pre-ESRD period and associated mortality in elderly patients, Am J Kidney Dis, 40, 1153, 10.1053/ajkd.2002.36861 Macdougall, 1996, A randomized controlled study of iron supplementation in patients treated with erythropoietin, Kidney Int, 50, 1694, 10.1038/ki.1996.487 Drueke, 2006, Normalization of hemoglobin level in patients with chronic kidney disease and anemia, N Engl J Med, 355, 2071, 10.1056/NEJMoa062276 Singh, 2006, Correction of anemia with epoetin alfa in chronic kidney disease, N Engl J Med, 355, 2085, 10.1056/NEJMoa065485 2007, KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target, Am J Kidney Dis, 50, 471, 10.1053/j.ajkd.2007.06.008 Stead, 2006, Evaluation of the safety and pharmacodynamics of hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers, Blood, 108, 1830, 10.1182/blood-2006-04-015818 Jelkmann, 2004, Molecular biology of erythropoietin, Intern Med, 43, 649, 10.2169/internalmedicine.43.649 Schofield, 2004, Oxygen sensing by HIF hydroxylases, Nat Rev Mol Cell Biol, 5, 43, 10.1038/nrm1366 Nangaku, 2006, Pathogenesis of renal anemia, Semin Nephrol, 26, 261, 10.1016/j.semnephrol.2006.06.001 Bernhardt, 2010, Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD, J Am Soc Nephrol, 21, 2151, 10.1681/ASN.2010010116 Haase, 2010, Hypoxic regulation of erythropoiesis and iron metabolism, Am J Physiol Renal Physiol, 299, F1, 10.1152/ajprenal.00174.2010 Besarab, 2010 Toffoli, 2009, Intermittent hypoxia is an angiogenic inducer for endothelial cells: role of HIF-1, Angiogenesis, 12, 47, 10.1007/s10456-009-9131-y Ingley, 2004, New insights into the regulation of erythroid cells, IUBMB Life, 56, 177, 10.1080/15216540410001703956 Imagawa, 2003, A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF alpha, or L-NMMA, FASEB J, 17, 1742, 10.1096/fj.02-1134fje Nakano, 2004, Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease, Blood, 104, 4300, 10.1182/blood-2004-04-1631 Brill-Almon, 2005, Ex vivo transduction of human dermal tissue structures for autologous implantation production and delivery of therapeutic proteins, Mol Ther, 12, 274, 10.1016/j.ymthe.2005.03.023